Several factors have been postulated to account for the propensity of HER2-positive breast cancer to metastasize to the CNS, including the prolonged survival of patients treated with anti-HER2 therapy, the limited intracranial activity of anti-HER2 therapy, and the inherent tropism of HER2 positive breast cancer to the brain. The gene discussed is ERBB2; the disease is breast cancer.